Immune checkpoint inhibitors are now the standard of care for almost all of our patients with non-small cell lung cancer. And here to give us a look into how that’s impacted our patients and practices is Dr. Stephen Liu, Associate Professor of Medicine at the Lombardi Comprehensive Cancer Center of Georgetown University.